待处理
入排:排除
图源:待检查
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials.
Gil Yosipovitch, Kim Papp, Seth Forman, George Han, Jill Waibel, Maria J Rueda, Luna Sun, Yun-Fei Chen, Orin Goldblum, Evangeline Pierce, Jonathan I Silverberg
Br J Dermatol 186(6) 1047-1049
摘要
摘要
With data from three monotherapy baricitinib phase III randomized clinical trials (RCTs), we conducted a posthoc mediator analysis to assess whether changes in itch or skin severity mediated the treatment effect over placebo on changes in health-related quality of life. In this analysis, baricitinib demonstrated significant improvement in the Dermatology Life Quality Index for which itch mediated approximately half of the changes at weeks 4 and 16.
KM 提取结果
0 个 Figure · 0 个 KM 面板